{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:36:14Z","timestamp":1789245374170,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.ajkd.2022.06.013","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T02:10:50Z","timestamp":1662084650000},"page":"294-306.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population"],"prefix":"10.1053","volume":"81","author":[{"given":"Xueqing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajohnsak","family":"Noppakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Gilbride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beulah","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Okily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2022.06.013_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acr.20648","article-title":"Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort","volume":"64","author":"Urowitz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1191\/9612332lu155oa","article-title":"Baseline characteristics of a multiethnic lupus cohort: PROFILE","volume":"11","author":"Alarcon","year":"2002","journal-title":"Lupus"},{"issue":"9","key":"10.1053\/j.ajkd.2022.06.013_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002891","article-title":"Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)","volume":"95","author":"Galindo-Izquierdo","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1574887112666171123113200","article-title":"Lupus nephritis: current treatment paradigm and unmet needs","volume":"13","author":"Menez","year":"2018","journal-title":"Rev Recent Clin Trials"},{"issue":"8","key":"10.1053\/j.ajkd.2022.06.013_bib6","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","article-title":"Survival analysis and causes of mortality in patients with lupus nephritis","volume":"27","author":"Yap","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1053\/j.ajkd.2022.06.013_bib7","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1001\/archinte.160.20.3136","article-title":"Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995","volume":"160","author":"Ward","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1053\/j.ajkd.2022.06.013_bib8","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/art.22079","article-title":"The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient","volume":"54","author":"Patel","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2022.06.013_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1053\/j.ajkd.2022.06.013_bib10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0961203313502571","article-title":"Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes","volume":"22","author":"Gonzalez","year":"2013","journal-title":"Lupus"},{"issue":"11","key":"10.1053\/j.ajkd.2022.06.013_bib11","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0961203313499086","article-title":"Chinese SLE Treatment and Research Group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus","volume":"22","author":"Li","year":"2013","journal-title":"Lupus"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1053\/j.ajkd.2022.06.013_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-018-4259-z","article-title":"Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort","volume":"38","author":"Wu","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000430458","article-title":"Lupus nephritis in Asia: clinical features and management","volume":"1","author":"Yap","year":"2015","journal-title":"Kidney Dis (Basel)"},{"issue":"33","key":"10.1053\/j.ajkd.2022.06.013_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021121","article-title":"Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: A PRISMA-compliant meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ajkd.2022.06.013_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.12136","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"19","author":"Mok","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"10.1053\/j.ajkd.2022.06.013_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2022.06.013_bib18","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1053\/j.ajkd.2022.06.013_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2022.06.013_bib26","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1053\/j.ajkd.2022.06.013_bib27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.06.013_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A\u00a0secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2022.06.013_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A\u00a0pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2022.06.013_bib30","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1053\/j.ajkd.2022.06.013_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622008605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622008605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:48:32Z","timestamp":1759463312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622008605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0272638622008605"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}